Metastatic colorectal carcinoma patients: The Glasgow Prognostic Score (GPS) at the era of anti-EGFR therapies

被引：0
|
作者：
Dreanic, J. [1 ]
Maillet, M. [1 ]
Dhooge, M. [1 ]
Cessot, A. [2 ]
Mir, O. [2 ]
Brezault, C. [1 ]
Goldwasser, F. [2 ]
Chaussade, S. [1 ]
Coriat, R. [1 ]
机构：
[1] Paris Descartes Univ, Cochin Teaching Hosp, AP HP, Dept Gastroenterol, Paris, France
[2] Paris Descartes Univ, Cochin Teaching Hosp, AP HP, Dept Oncol, Paris, France
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2290
引用
收藏
页码：S525 / S525
页数：1
相关论文
共 50 条
  • [31] Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis
    Kassouf, Elie
    Tabchi, Samer
    Tehfe, Mustapha
    BIODRUGS, 2016, 30 (02) : 95 - 104
  • [32] Place of anti-EGFR therapy in older patients with metastatic colorectal cancer in 2020
    Gilabert, Marine
    Ries, Pauline
    Chanez, Brice
    Triby, Simon
    Francois, Eric
    Lievre, Astrid
    Rousseau, Frederique
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (08) : 1229 - 1236
  • [33] Modified Glasgow Prognostic Score 2 as a Prognostic Marker in Patients With Metastatic Urothelial Carcinoma
    Nagai, Takashi
    Naiki, Taku
    Isobe, Teruki
    Sugiyama, Yosuke
    Etani, Toshiki
    Iida, Keitaro
    Nozaki, Satoshi
    Noda, Yusuke
    Shimizu, Nobuhiko
    Tasaki, Yoshihiko
    Mimura, Yoshihisa
    Banno, Rika
    Kubota, Hiroki
    Hamamoto, Shuzo
    Kawai, Noriyasu
    Yasui, Takahiro
    IN VIVO, 2021, 35 (05): : 2793 - 2800
  • [34] IMMUNOLOGICAL EFFECTS OF DIFFERENT ANTI-EGFR ANTIBODIES IN METASTATIC COLORECTAL CANCER PATIENTS
    Manzoni, M.
    Delfanti, S.
    Rovati, B.
    Brugnatelli, S.
    Ronzoni, M.
    Perfetti, V
    Mariucci, S.
    Loupakis, F.
    Danova, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 33 - 33
  • [35] EGFR protein expression of the metastatic colorectal cancer as a prognostic/predictive factor for anti-EGFR antibody therapy.
    Timar, Jozsef
    Piurko, Violetta
    Kenessey, Istvan
    Raso, Erzsebet
    Lahm, Erika
    Kiss, Edina
    Sikter, MArta
    Vachaja, Jozsef
    Papai, Zsuzsa
    Uhlyarik, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer
    Rosati, Gerardo
    Montrone, Michele
    Pacilio, Carmen
    Colombo, Alfredo
    Cicero, Giuseppe
    Paragliola, Fernando
    Vaia, Angelo
    Annunziata, Luigi
    Bilancia, Domenico
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (23)
  • [37] A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients
    Bonin, Serena
    Donada, Marisa
    Bussolati, Gianni
    Nardon, Ermanno
    Annaratone, Laura
    Pichler, Martin
    Chiaravalli, Anna Maria
    Capella, Carlo
    Hoefler, Gerald
    Stanta, Giorgio
    TUMOR BIOLOGY, 2016, 37 (06) : 7295 - 7303
  • [38] Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer
    Annunziata, Maria Carmela
    De Stefano, Alfonso
    Fabbrocini, Gabriella
    Leo, Silvana
    Marchetti, Paolo
    Romano, Maria Concetta
    Romano, Ivana
    CLINICAL DRUG INVESTIGATION, 2019, 39 (09) : 825 - 834
  • [39] Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer
    Maria Carmela Annunziata
    Alfonso De Stefano
    Gabriella Fabbrocini
    Silvana Leo
    Paolo Marchetti
    Maria Concetta Romano
    Ivana Romano
    Clinical Drug Investigation, 2019, 39 : 825 - 834
  • [40] The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies
    Meriggi, Fausto
    Vermi, William
    Bertocchi, Paola
    Zaniboni, Alberto
    REVIEWS ON RECENT CLINICAL TRIALS, 2014, 9 (01) : 8 - 12
12345